$SSRT

Abeona Therapeutics has reported its Q4 2025 earnings, revealing a narrower loss than expected, which is generally seen as a positive sign. The company has made significant progress in its clinical trials for gene therapies, which has shown promising results and increased investor confidence. Additionally, their recent partnerships for drug development could enhance their growth prospects. However, concerns remain regarding regulatory hurdles and competition within the gene therapy sector. Overall, the sentiment appears to be cautiously optimistic as Abeona seeks to stabilize its financial health moving forward.